A trio of Gen Z venture capitalists recently hosted a black-tie peptide party aboard the SS Jeremiah O'Brien, a World War II Liberty ship built in 56 days that once supplied Allied powers during Normandy. The unusual venue served as a deliberate backdrop for a serious conversation about American industrial prowess and the pharmaceutical supply chain. Organized by Roxana Grunenwald, Yuva Krishnapillai, and Elia Ahmadi from the biotech accelerator Haus Fund, the event brought together roughly 150 attendees to discuss the future of peptides and the push to bring their production onto American soil.
The timing of the gathering follows a controversial interim policy decision from the US Department of Health and Human Services allowing certain unapproved peptides for compounding. While FDA career scientists previously stated there is insufficient evidence proving safety or efficacy for these experimental peptides, supporters of the decision argue it provides a first step toward solving the gray-market problem. Currently, the vast majority of consumer research peptides sold online come from overseas manufacturers, particularly in China. Industry advocates and investors argue that domestic production is necessary to give American consumers recourse, ensure regulatory consistency, and establish higher standards of quality and safety.
Key takeaways
- Haus Fund organizers hosted a peptide event on a WWII ship to advocate for US-based pharmaceutical manufacturing.
- The HHS recently issued a controversial interim policy decision allowing certain unapproved peptides for compounding.
- Telehealth company Hims & Hers recently purchased an API manufacturing facility in California.
- Hims & Hers plans to launch Peptides Plus, featuring substances like Sermorelin, Glutathione, B12, NAD+, L-carnitine, and eventually BPC-157 and TB-500.
The Push for Domestic API Infrastructure
According to data from the US Pharmacopeia, 51 percent of all US prescription active pharmaceutical ingredients come from India and the European Union, while China accounts for 10 percent. However, for gray-market research chemicals, Chinese manufacturers supply the vast majority. Organizers from Haus Fund draw parallels to the hardware and semiconductor industries, which have increasingly recognized the risks of relying heavily on foreign supply chains for critical components. They argue that the biotechnology sector must undergo a similar realization.
Building out an end-to-end domestic supply chain for peptides is an expensive and complex undertaking. Cost remains a major factor for consumers who currently turn to overseas sellers, meaning American-made peptides will likely carry a higher price tag. Despite the financial and operational hurdles, some companies are already moving forward with domestic infrastructure investments.
Corporate Investments and Upcoming Services
Major telehealth players are also jumping into the American peptide movement. Dr. Anant Vinjamoori, chief medical officer at Hims & Hers, noted that the company purchased an API manufacturing facility in California last year with the intention of providing US-made active pharmaceutical ingredients and finished products throughout the entire supply chain. This facility purchase coincides with the upcoming launch of Peptides Plus, a service announced by Hims & Hers following the HHS interim policy decision.
According to announcements from Hims & Hers CEO Andrew Dudum, the company has spent years building the necessary US-based peptide manufacturing infrastructure. At launch, the service plans to offer access to compounds such as Sermorelin, Glutathione, vitamin B12, NAD+, and L-carnitine, with BPC-157 and TB-500 slated to follow once allowable. While questions remain regarding how domestic manufacturing will impact final pricing and whether the interim HHS policy will lead to lasting regulatory changes, industry players expect to see a growing number of vendors marketing their peptides as proudly made in America.
Comments